School of Public Health, Peking University Health Science Center, Beijing, China.
Brown School, Washington University in St Louis, St Louis, Missouri, USA.
BMJ Open. 2023 Jan 30;13(1):e067683. doi: 10.1136/bmjopen-2022-067683.
Quality variation has been widely witnessed and discussed in China. However, limited evidence reveals quality gaps by the medical institute level, especially between hospitals and primary care institutes. This systematic review will synthesise the available evidence on quality variation between medical institutes at different levels in China. By adopting a quality framework, we will also explore the detailed domains (structure, process and outcomes) and dimensions (safety, effectiveness, timeliness, patient-centredness, efficiency, integration and equity) of quality gaps.
An extensive literature search will be conducted on eight key electronic databases: MEDLINE, Web of Science, Cochrane Library, Scopus, EMBASE, ProQuest, China National Knowledge Infrastructure and WANFANG database. The Grey Matter Checklist will be used to screen relevant grey literature. The publication time limit should be before 31 December 2022 when we plan to conduct a literature search. All kinds of studies that revealed the quality difference between medical institutes at different levels will be included, no matter if quality improvement intervention is involved. All quality measures and indicators will be recorded and sorted into appropriate domains and dimensions. For those studies that took the completion rate of standard operations to assess the quality, we will also record the name of the clinical pathways, guidelines or checklists used. Two reviewers will independently perform the study selection, data extraction and quality assessment process. A narrative or quantitative synthesis will be performed based on the available data.
Ethics approval is not applicable. The results of this study will be submitted to a widely accepted peer-review journal. The findings will also be used to inform administration about quality gaps by different medical institute levels and, therefore, help them to design policies that will minimise the quality variation.
CRD42022345933.
质量变化在中国已被广泛观察和讨论。然而,有限的证据揭示了不同医疗机构之间的质量差距,尤其是医院和基层医疗机构之间的差距。本系统评价将综合中国不同级别医疗机构质量变化的现有证据。通过采用质量框架,我们还将探索质量差距的详细领域(结构、过程和结果)和维度(安全性、有效性、及时性、以患者为中心、效率、整合和公平性)。
将在 8 个主要电子数据库中进行广泛的文献检索:MEDLINE、Web of Science、Cochrane 图书馆、Scopus、EMBASE、ProQuest、中国国家知识基础设施和万方数据库。将使用 Grey Matter Checklist 筛选相关灰色文献。计划进行文献检索时,应将出版时间限制在 2022 年 12 月 31 日之前。将纳入各种揭示不同级别医疗机构之间质量差异的研究,无论是否涉及质量改进干预。所有质量措施和指标都将被记录并归类到适当的领域和维度中。对于那些以标准操作完成率来评估质量的研究,我们还将记录所使用的临床路径、指南或检查表的名称。两名评审员将独立进行研究选择、数据提取和质量评估过程。将根据现有数据进行叙述性或定量综合。
不需要伦理批准。本研究的结果将提交给一个广泛认可的同行评审期刊。研究结果还将用于告知行政部门不同医疗机构水平的质量差距,并帮助他们设计政策,以尽量减少质量变化。
PROSPERO 注册号:CRD42022345933。